Companies formed

Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.

Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.

The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.


Improving the lives of people living with Parkinson’s.

Incorporated in March 2020

Origin: Oxford University, Physiology, Anatomy and Genetics

Contact: Richard Auburn


Malaria vaccine development.

Incorporated in September 2019

Origin: Oxford University, Jenner Institute

GryeOx addresses significant unmet need in drug discovery as the IP can make expanded drug libra of macrocycles in the hit to lead stage.

Incorporated in July 2019

Origin: Oxford University

DNA assembly.

Incorporated in July 2019

Origin: Oxford University

Platform technology based on NG capture-c technique computational pipelines and experimental know-how.

Incorporated in July 2019

Origin: Oxford University, MRC Weatherall Institute of Molecular Medicine

Contact: Matthew Carpenter

"CRIS" software that enables submission, de-identification and sharing of mental health patient records using a federated data and information governance model.

Incorporated in May 2019

Origin: Oxford University, Psychiatry


OxStem Immuno aims to develop small molecule drugs that augment macrophage efferocytosis in
vitro and enhance tissue repair in vivo. These therapies will supercede the need for cell transplantation
or cytokine therapy in the context of tissue repair for chronic wounds and a range of inflammatory

Incorporated in December 2018

Origin: Oxford University, Department of Physiology, Anatomy and Genetics

Contact: Adam Workman

OxStem Beta will generate novel therapies to stimulate formation of new beta cells in the pancreas
(neogenesis) by targeting pathways that are normally only active during development or following
pancreatic injury.

Incorporated in December 2018

Origin: Oxford University, Pathology

A not for profit company providing a solution and accreditation to businesses that work to bring their workforce out of multidimensional poverty

Incorporated in November 2018

Origin: Oxford University, International Development

Contact: Mark Mann

Ready to get in touch?

Contact Us
© Oxford University Innovation